Insights into the mechanism of C5aR inhibition by PMX53 via implicit solvent molecular dynamics simulations and docking

BMC Biophysics

Volumn 7, Issue 1, 2014, Pages

  Tamamis, Phanourios ^a   Kieslich, Chris A ^b   Nikiforovich, Gregory V ^c   Woodruff, Trent M ^d   Morikis, Dimitrios ^b   Archontis, Georgios ^a  

^a UNIVERSITY OF CYPRUS   (Cyprus)

^b University of California Riverside   (United States)

^c MolLife Design LLC   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

C5a; C5aR; Class A GPCR; Complement system; Docking; Implicit solvent; Membrane protein; Molecular dynamics

Indexed keywords

EID: 84928156402     PISSN: 20461682     EISSN: None     Source Type: Journal    
DOI: 10.1186/2046-1682-7-5     Document Type: Article

References (68)

1. Manthey HD, Woodruff TM, Taylor SM, Monk PN. Complement component 5a (C5a). Int J Biochem Cell Biol 2009, 41:2114-2117.
2. Monk PN, Scola A-M, Madala P, Fairlie DP. Function, structure and therapeutic potential of complement C5a receptors. British J Pharm 2007, 152:429-448.
3. Klos A, Wende E, Wareham KJ, Monk PN. International union of basic and clinical pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharm Rev 2013, 65:500-543.
4. Li R, Coulthard LG, Wu MC, Taylor SM, Woodruff TM. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J 2013, 27:855-864.
5. Higginbottom A, Cain SA, Woodruff TM, Proctor LM, Madala PK, Tyndall JDA, Taylor SM, Fairlie DP, Monk PN. Comparative Agonist/Antagonist responses in mutant human C5a receptors define the ligand binding site. J Biol Chem 2005, 280:17831-17840.
6. Woodruff TM, Strachan AJ, Dryburgh N, Shiels IA, Reid RC, Fairlie DP, Taylor SM. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum 2002, 46:2476-2485.
7. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD. Modulation of the anti-tumor immune response by complement. Nat Immunol 2008, 9:1225-1235.
8. Woodruff TM, Ager RR, Tenner AJ, Noakes PG, Taylor SM. The role of the complement system and the activation fragment C5a in the central nervous system. Neruomol Med 2010, 12:179-192.
9. Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol 2011, 48:1631-1642.
10. Wong KA, Finch AM, Pierens GK, Craik DJ, Taylor SM, Fairlie DP. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a. J Med Chem 1998, 41:3417-3425.
11. Finch AM, Wong AK, Paczkowski NJ, Wadi SK, Craik DJ, Fairlie DP, Taylor SM. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem 1999, 42:1965-1974.
12. Woodruff TM, Strachan AJ, Sanderson SD, Monk PN, Wong AK, Fairlie DP, Taylor SM. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Inflammation 2001, 25:171-177.
13. Morgan M, Bulmer AC, Woodruff TM, Proctor LM, Williams HM, Stocks SZ, Pollitt S, Taylor SM, Shiels IA. Pharmacokinetics of a C5a receptor antagonist in the rat after different sites of enteral administration. Eur J Pharm Sci 2008, 33:390-398.
14. Granier S, Kobilka B. A new era of GPCR structural and chemical biology. Nat Chem Biol 2012, 8:670-673.
15. Rasmussen S, DeVree BT, Zou Y, Kruse AC, Chang KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, Mathiesen JM, Shah STA, Lyons JA, Caffrey M, Gellman SH, Steyaert J, Skiniotis G, Weis WI, Sunahara RK, Kobilka BK. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 2011, 477:549-555.
16. Wu H, Wacker D, Mileni M, Katritch V, Han GW, Vardy E, Liu W, Thompson AA, Huang X-P, Carroll FI, Mascarella SW, Westkaemper RB, Mosier PD, Roth BL, Cherezov V, Stevens RC. Structure of the human κ-opioid receptor in complex with JDTic. Nature 2012, 485:327-333.
17. Thompson AA, Liu W, Chun E, Katritch V, Wu H, Vardy E, Huang X-P, Trapella C, Guerrini R, Calo G, Roth BL, Cherezov V, Stevens RC. Structure of the Nociceptin/Orphanin FQ receptor in complex with a peptide mimetic. Nature 2012, 485:395-401.
18. Haga K, Kruse AC, Asada H, Yurugi-Kobayashi T, Shiroishi M, Zhang C, Weis WI, Okada T, Koblika BK, Haga T, Kobayashi T. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 2012, 482:547-551.
19. Kruse AC, Hu J, Pan AC, Arlow DH, Rosenbaum DM, Rosemond E, Green HF, Liu T, Chae PS, Dror RO, Shaw DE, Weis WE, Wess J, Kobilka BK. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 2012, 482:552-556.
20. Dror RO, Dirks RM, Grossman JP, Xu H, Shaw DE. Biomolecular simulation: a computational microscope for molecular biology. Annu Rev Biophys 2012, 41:429-452.
21. Michino M, Chen J, Stevens RC, Brooks CL. FoldGPCR: structure prediction protocol for the transmembrane domain of G protein-coupled receptors from class A. Proteins 2010, 78:2189-2201.
22. Thayer AM. Improving peptides. Chem Eng News 2011, 89(22):13-20.
23. Nikiforovich GV, Marshall GR. Modeling flexible loops in the dark-adapted and activated states of rhodopsin, a prototypical G-protein-coupled receptor. Biophys J 2005, 89:3780-3789.
24. Matsumoto ML, Narzinski K, Kiser PD, Nikiforovich GV, Baranski TJ. A comprehensive structure-function map of the intracellular surface of the human C5a receptor. I. Identification of critical residues. J Biol Chem 2007, 282:3105-3121.
25. Nikiforovich GV, Marshall GR, Baranski TJ. Modeling molecular mechanisms of binding of the anaphylatoxin C5a to the C5a receptor. Biochemistry 2008, 47:3117-3130.
26. Hagemann IS, Miller DL, Kico JM, Nikiforovich GV, Baranski TJ. Structure of the complement factor 5a receptor-ligand complex studied by disulfide trapping and molecular modeling. J Biol Chem 2008, 283:7763-7775.
27. Nikiforovich GV, Baranski TJ. Structural mechanisms of constitutive activation in the C5a receptors with mutations in the extracellular loops: molecular modeling study. Proteins 2012, 80:71-80.
28. Zhang L, Mallik B, Morikis D. Structural study of Ac-Phe-[Orn-Pro-dCha-Trp-Arg], a potent C5a recptor antagonist by NMR. Peptide Sci 2008, 90:803-815.
29. Im W, Feig M, Brooks CL. An implicit membrane generalized born theory for the study of structure, stability, and interactions of membrane proteins. Biophys J 2003, 85:2900-2918.
30. Lee MS, Feig M, Salzbury FR, Brooks CL. New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations. J Comp Chem 2003, 24:1348-1356.
31. Tanizaki S, Feig M. A generalized Born formalism for heterogeneous dielec- tric environments: application to the implicit modeling of biological membranes. J Chem Phys 2005, 122:124706.
32. Feig M, Brooks CL. Recent advances in the development and application of implicit solvent models in biomolecule simulations. Curr Op Struct Biol 2004, 14:217-224.
33. Yuzlenko O, Lazaridis T. Membrane protein native state discrimination by implicit membrane models. J Comp Chem 2013, 34:731-738.
34. MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiorkiewicz-Kuczera J, Yin D, Karplus M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 1998, 102:3586-3616.
35. Mackerell AD, Feig M, Brooks CL. Extending the treatment of backbone energetics in protein force fields: limitations of gas- phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J Comput Chem 2004, 25:1400-1415.
36. Brooks BR, Brooks CL, Mackerell AD, Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C, Boresch S, Caflisch A, Caves L, Cui Q, Dinner AR, Feig M, Fischer S, Gao J, Hodoscek M, Im W, Kuczera K, Lazaridis T, Ma J, Ovchinnikov V, Paci E, Pastor RW, Post CB, Pu JZ, Schaefer M, Tidor B, Venable RM, et al. CHARMM: the biomolecular simulation program. J Comput Chem 2009, 30:1545-1614.
37. Karpen ME, Tobias DJ, Brooks CL. Statistical clustering techniques for analysis of long molecular dynamics trajectories. I: analysis of 2.2 ns trajectories of YPGDV. Biochemistry 1993, 32:412-420.
38. Carpenter GA, Grossberg S. ART-2: self-organization of stable category recognition codes for analog input patterns. Appl Opt 1987, 26:4919-4930.
39. Nikiforovich GV, Taylor CM, Marshall GR. Modeling of the complex between transducin and photoactivated rhodopsin, a prototypical G-protein-coupled receptor. Biochemistry 2007, 46:4734-4744.
40. The UniProt Consortium Update on activities at the Universal Protein Resource (UniProt) in 2013. Nucleic Acids Res 2013, 41:D43-D47. The UniProt Consortium.
41. Lomize MA, Lomize LA, Pogozheva ID, Mosberg HI. OPM: orientations of proteins in membranes database. Bioinformatics 2006, 22:623-625.
42. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 1997, 23:327-341.
43. Jaccard P. Étude comparative de la distribution florale dans une portion des Alpes et des Jura. Bulletin de la Société Vaudoise des Sciences Naturelles 1901, 37:547-579.
44. Jain A, Murty M, Flynn P. Data clustering: a review. ACM Comput Surv 1999, 31:264-323.
45. R Development Core Team R: A language and environment for statistical computing. R Foundation for Statistical Computing 2011, Vienna, Austria: R Development Core Team, R Development Core Team.
46. Grant BJ, Rodrigues APC, ElSawy KM, McCammon JA, Caves LSD. Bio3D. A package for the comparative analysis of protein structures. Bioinformatics 2006, 22:2695-2696.
47. Lang PT, Brozell SR, Mukherjee S, Pettersen EF, Meng EC, Thomas V, Rizzo RC, Case DA, James TL, Kuntz ID. DOCK 6: combining techniques to model RNA-small molecule complexes. RNA 2009, 15:1219-1230.
48. Richards FM. Areas, volumes, packing, and protein structure. Ann Rev Biophys Bioeng 1977, 6:151-176.
49. Massova I, Kollman PA. Combined molecular mechanical and con- tinuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. Perspect Drug Discov Des 2000, 18:113-135.
50. Pearlman DA. Evaluating the molecular mechanics Poisson-Boltzmann surface area free energy method using a congeneric series of ligands to p38 MAP kinase. J Med Chem 2005, 48:7796-7807.
51. Hayes JM, Archontis G. MM-GB (PB) SA Calculations of Protein-Ligand Binding Free Energies, Molecular Dynamics - Studies of Synthetic and Biological Macromolecules. Tech, Chapter 9 2012, 171-190. Wang L.
52. Seeber M, Felline A, Raimondi F, Muff S, Friedman R, Rao F, Caflisch A, Fanelli F. Wordom: a user-friendly program for the analysis of molecular structures, trajectories, and free energy surfaces. J Comp Chem 2011, 32:1183-1194.
53. Tamamis P, Morikis D, Floudas CA, Archontis G. Species specificity of the complement inhibitor compstatin investigated by all-atom molecular dynamics simulations. Proteins 2010, 78:2655-2667.
54. Tamamis P, Pierou P, Mytidou C, Floudas CA, Morikis D, Archontis G. Design of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: the case of C3 inhibition by compstatin. Proteins 2011, 79:3166-3179.
55. Findlay JB, Pappin DJ. The Opsin family of proteins. Biochem J 1986, 238:625-642.
56. Nikiforovich GV, Marshall GR, Baranski TJ. Simplified modeling approach suggests structural mechanisms for constitutive activation of the C5a receptor. Proteins 2011, 79:787-802.
57. Nikiforovich GV, Taylor CM, Marshall G, Baranski TJ. Modeling the possible conformations of the extracellular receptors in G-protein-coupled receptors. Proteins 2010, 78:271-285.
58. Gerber BO, Meng EC, Doetsch V, Baranski TJ, Bourne HR. An activation switch in the ligand binding pocket of the C5a receptor. J Biolog Chem 2001, 276:3394-3400.
59. Cain SA, Coughlan T, Monk PN. Mapping the ligand-binding site on the C5a receptor: arginine 74 of C5a contacts aspartate 282 of the C5a receptor. Biochemistry 2001, 40:14047-14052.
60. Cain SA, Higginbottom A, Monk PN. Characterisation of C5a receptor agonists from phage display libraries. Biochem Pharmacol 2003, 66:1833-1840.
61. March DR, Proctor LM, Stoermer MJ, Sbaglia R, Abbenante G, Reid CR, Woodruff TM, Wadi K, Paczkowski N, Tyndall JDA, Taylor SM, Fairlie D. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structure and activity. Molec Pharmacol 2004, 65:868-879.
62. Maiti R, Van Domselaar GH, Zhang H, Wishart DS. SuperPose: a simple server for sophisticated structural superposition. Nucleic Acids Res 2004, 32(Web Server issue):W590W594.
63. Tamamis P, de Victoria López A, Gorham RD, Bellows-Peterson ML, Pierou P, Floudas CA, Morikis D, Archontis G. Molecular dynamics in drug design: new generations of compstatin analogs. Chem Biol Drug Des 2012, 79:703-718.
64. Gilson MK, Zhou H-X. Calculation of protein-ligand binding affinities. Annu Rev Biophys Biomol Struct 2007, 36:21-42.
65. Tamamis P, Floudas CA. Molecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loop. Biophys J 2013, 105:1502-1514.
66. Tamamis P, Floudas CA. Molecular recognition of CCR5 by an HIV-1 gp120 V3 Loop. PLoS ONE 2014, 9:e95767.
67. Tamamis P, Floudas CA. Elucidating a key component of cancer metastasis: CXCL12 (SDF-1α) binding to CXCR4. J Chem Inf Model 2014, 54:1174-1188.
68. Tamamis P, Floudas CA. Elucidating a key anti-HIV-1 and cancer-associated axis: the structure of CCL5 (Rantes) in complex with CCR5. Sci Rep 2014, 4:5447.